Search research articles
Contact Us
Filters
Showing results (81-90 of 100) with videos related to
Page
of 10
Sort By:
British Journal of Cancer
|
April 25, 2007
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients
E de Azambuja, F Cardoso, G de Castro, et al.
International Journal of Breast Cancer
|
July 11, 2014
Early invasive cancer and partial intraoperative electron radiation therapy of the breast: experience of the jules bordet institute
C Philippson, S Simon, C Vandekerkhove, et al.
International Journal of Oncology
|
December 5, 2003
Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer
F Cardoso, V Durbecq, D Larsimont, et al.
Annales D'Endocrinologie
|
January 1, 1997
[Belgian registry of thyroid cancer. Preliminary epidemiological characteristics revealed by a retrospective study (1988-1995). Belgian Thyroid Cancer Study Group]
M Meurisse, N Claeys, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2003
Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
H Bonnefoi, S Diebold-Berger, P Therasse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2000
A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer
A Di Leo, J Crown, J M Nogaret, et al.
British Journal of Cancer
|
March 23, 2013
Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients
P El Hajj, F Journe, M Wiedig, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 21, 2007
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial
A Di Leo, M Tanner, C Desmedt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 19, 2003
Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients
C Bernard-Marty, M Mano, M Paesmans, et al.
Clinical Breast Cancer
|
March 20, 2002
A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923
A Hamilton, D Larsimont, R Paridaens, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 100) with videos related to
Sort By:
Page
of 10
British Journal of Cancer
|
April 25, 2007
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients
E de Azambuja, F Cardoso, G de Castro, et al.
International Journal of Breast Cancer
|
July 11, 2014
Early invasive cancer and partial intraoperative electron radiation therapy of the breast: experience of the jules bordet institute
C Philippson, S Simon, C Vandekerkhove, et al.
International Journal of Oncology
|
December 5, 2003
Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer
F Cardoso, V Durbecq, D Larsimont, et al.
Annales D'Endocrinologie
|
January 1, 1997
[Belgian registry of thyroid cancer. Preliminary epidemiological characteristics revealed by a retrospective study (1988-1995). Belgian Thyroid Cancer Study Group]
M Meurisse, N Claeys, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2003
Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
H Bonnefoi, S Diebold-Berger, P Therasse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2000
A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer
A Di Leo, J Crown, J M Nogaret, et al.
British Journal of Cancer
|
March 23, 2013
Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients
P El Hajj, F Journe, M Wiedig, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 21, 2007
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial
A Di Leo, M Tanner, C Desmedt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 19, 2003
Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients
C Bernard-Marty, M Mano, M Paesmans, et al.
Clinical Breast Cancer
|
March 20, 2002
A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923
A Hamilton, D Larsimont, R Paridaens, et al.
Page
of 10